New approach for cell therapy shows potential against solid tumors with KRAS mutations

CNIO researchers clarify the role of the two isoforms of KRAS, the most common oncogene in humans

Newly approved targeted therapy sotorasib prolongs survival in KRAS G12C-mutated lung cancer

Immunotherapy alone extended life for metastatic lung cancer patients with KRAS mutation